Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial.

doi:10.1158/1078-0432.CCR-24-0268

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2024

Loree Jonathan M, Titmuss Emma, Topham James T, Kennecke Hagen F, Feilotter Harriet, Virk Shakeel, Lee Young S, Banks Kimberly, Quinn Katie, Karsan Aly, Renouf Daniel J, Jonker Derek J, Tu Dongsheng, O'Callaghan Chris J, Chen Eric X

Abstract excerpt

PURPOSE: Tissue-derived tumor mutation burden (TMB) of ≥10 mutations/Mb is a histology-agnostic biomarker for the immune checkpoint inhibitor (ICI) pembrolizumab. However, the dataset in which this was validated lacked colorectal cancers (CRC), and there is limited evidence for immunotherapy benefits in CRC using this threshold. PATIENTS AND METHODS: CO.26 was a randomized phase II study of 180 patients,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Biomarkers, Tumor

Share to Circulating Tumor DNA

Share to Colorectal Neoplasms

Share to Immune Checkpoint Inhibitors

Share to Neoplasm Metastasis

Source

Open in PubMed Open full text

Identifiers

PMID: 38727700
DOI: 10.1158/1078-0432.CCR-24-0268
PMCID: PMC11292199

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial.PMID 38727700Read ↗

Tumor mutational burden in colorectal cancer: Implications for treatment.Semantic proximity Read ↗

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.Semantic proximity Read ↗

Interplay between Tumor Mutational Burden and Mutational Profile and its effect on overall survival: A Post Hoc Analysis of Metastatic Patients Treated with Immune Checkpoint InhibitorsSemantic proximity Read ↗

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.Semantic proximity Read ↗

Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.Semantic proximity Read ↗

Validity and utility of blood tumor mutational burden is dependent on circulating tumor DNA shedSemantic proximity Read ↗

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Semantic proximity Read ↗

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours.Semantic proximity Read ↗

Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker in Solid TumorsSemantic proximity Read ↗

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.